The incidence of gastrointestinal perforations among rheumatoid arthritis patients
- PMID: 20967860
- PMCID: PMC3031757
- DOI: 10.1002/art.30107
The incidence of gastrointestinal perforations among rheumatoid arthritis patients
Abstract
Objective: Gastrointestinal (GI) perforation has emerged as a novel safety concern in relation to medications used to treat rheumatoid arthritis (RA). This study was undertaken to characterize the incidence and risk factors for GI perforation in RA patients.
Methods: Using administrative databases of a large US health plan, we identified RA patients treated with biologic agents, methotrexate (MTX), oral glucocorticoids, and nonsteroidal antiinflammatory drugs (NSAIDs). Additional risk factors we evaluated included diverticulitis. Hospitalization with GI perforation was identified using a validated algorithm. Incidence rates and risk factors were evaluated using Cox proportional hazards models.
Results: Among 40,841 RA patients, 37 hospitalizations with GI perforation were identified. The rate of GI perforation among patients currently being treated with biologic agents who were also receiving oral glucocorticoids was higher (1.12 per 1,000 person-years [95% confidence interval (95% CI) 0.50-2.49]) than for patients being treated with biologic agents who were not also receiving glucocorticoids (0.47 per 1,000 person-years [95% CI 0.22-0.98]) or for patients being treated with MTX who were also receiving glucocorticoids (0.87 per 1,000 person-years [95% CI 0.36-2.10]). Neither biologic agents nor MTX was significantly associated with GI perforation, in contrast to current treatment with glucocorticoids and NSAIDs together (hazard ratio 4.7 [95% CI 1.9-12.0]) or glucocorticoids alone (hazard ratio 2.8 [95% CI 1.3-6.1]). Diverticulitis also was a strong risk factor (hazard ratio 9.1 [95% CI 3.1-26.4]). Seventy percent of patients with GI perforation received glucocorticoids, had antecedent diverticulitis, or both.
Conclusion: GI perforation is an uncommon but serious adverse event among RA patients. Because a majority of patients with GI perforation were being treated with glucocorticoids or had previously experienced diverticulitis, these individuals should be considered at higher risk.
Copyright © 2011 by the American College of Rheumatology.
Similar articles
-
Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis.Arthritis Care Res (Hoboken). 2012 Dec;64(12):1819-28. doi: 10.1002/acr.21764. Arthritis Care Res (Hoboken). 2012. PMID: 22730417 Free PMC article.
-
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.Arthritis Rheumatol. 2016 Nov;68(11):2612-2617. doi: 10.1002/art.39761. Arthritis Rheumatol. 2016. PMID: 27213279 Free PMC article.
-
Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.RMD Open. 2020 Jul;6(2):e001201. doi: 10.1136/rmdopen-2020-001201. RMD Open. 2020. PMID: 32669452 Free PMC article.
-
Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.Clin Rheumatol. 2011 Nov;30(11):1471-4. doi: 10.1007/s10067-011-1827-x. Epub 2011 Aug 11. Clin Rheumatol. 2011. PMID: 21833686 Review.
-
Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.Drug Saf. 2018 Jun;41(6):545-553. doi: 10.1007/s40264-018-0639-1. Drug Saf. 2018. PMID: 29392593 Review.
Cited by
-
Spontaneous Sigmoid Colon Perforation and Ruptured Subserosal ("Zebra" Pattern) Small-Bowel Hematomas in Type IV Ehlers-Danlos Syndrome: A Case Report and a Short Review.J Clin Med. 2024 Jul 12;13(14):4093. doi: 10.3390/jcm13144093. J Clin Med. 2024. PMID: 39064133 Free PMC article.
-
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.Ann Rheum Dis. 2024 Oct 21;83(11):1454-1464. doi: 10.1136/ard-2023-225473. Ann Rheum Dis. 2024. PMID: 38955475 Free PMC article. Clinical Trial.
-
Impact of upadacitinib on the risk of digestive events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials.Heliyon. 2023 Jun 4;9(6):e17002. doi: 10.1016/j.heliyon.2023.e17002. eCollection 2023 Jun. Heliyon. 2023. PMID: 37484342 Free PMC article.
-
Comparison of the risk of gastrointestinal perforation between patients with and without rheumatoid arthritis: A nationwide cohort study in Asia.Front Med (Lausanne). 2022 Sep 29;9:974328. doi: 10.3389/fmed.2022.974328. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36250072 Free PMC article.
-
Effects of Systemic Lupus Erythematosus on Clinical Outcomes and In-Patient Mortality Among Hospitalized Patients With Diverticulitis.Cureus. 2022 Jul 6;14(7):e26603. doi: 10.7759/cureus.26603. eCollection 2022 Jul. Cureus. 2022. PMID: 35936158 Free PMC article.
References
-
- Van Vollenhoven RFKE, Furie R, Blesch A, Wang C, Curtis JR. Gastrointestinal Safety in Patients with Rheumatoid Arthritis Treated with Tocilizumab: Data From Roche Clinical Trials. American College of Rheumatology ACR/ARHP Annual Scientific Meeting; Philadelphia, PA. 2009.
-
- Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003 Nov 1;158(9):915–20. - PubMed
-
- Rothman KJ. Epidemiology. New York: Oxford University Press; 2002.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
